Drugs / PF-03049423
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT01208233 | Dec 2010 → Dec 2013 | ischemic stroke | Pfizer | Terminated | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01161069 Comparator | Aug → Dec 2009 | — | Pfizer | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-03049423 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01208233 ↗ |
| Action | Inhibit | “phosphodiesterase-5 inhibitor PF-03049423” PMID 26738812 ↗ Dec 20151“Phosphodiesterase 5A inhibitor” CHEMBL591501 ↗ |
| Modality | Small molecule | — CHEMBL591501 ↗ |
| Route | Oral | “PF-03049423 in oral solution, 2.5 mg, given once daily for 14 days; healthy young adult volunteers” NCT01161069 ↗ |
| Target | PDE5A | “Phosphodiesterase 5A inhibitor” CHEMBL591501 ↗ |